Skip to main content
SpringerLink
Log in

The Pharmacoeconomics of Hormone Replacement Therapy

  • Review Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Hormone replacement therapy (HRT) is a highly cost-effective treatment for symptoms of the menopause such as hot flushes (flashes). A number of economic evaluations have indicated that it may also be a cost-effective therapy for the prevention of cardiovascular disease and osteoporosis. However, these evaluations are based on the premise that HRT will reduce cardiovascular disease by 30 to 50%. Recent evidence casts doubt on its effectiveness at preventing cardiovascular disease, certainly as a secondary preventive therapy. Furthermore, HRT is likely to increase the incidence of breast cancer. If the effect of HRT on the cardiovascular system is slight or nonexistent, but its effect on breast cancer is modest or strong, then HRT is unlikely to be a cost-effective treatment for asymptomatic women at low risk of osteoporosis. However, the unwanted effects of HRT on the breast may be significantly reduced by targeting therapy to those women with low bone mass and who have other risk factors for fracture. Such a strategy is likely to be more cost effective than a strategy which allows asymptomatic women with low fracture risk to take HRT in the long term. As selective estrogen receptor modulators (SERMs) aggravate menopausal symptoms they are not likely to be an alternative for most perimenopausal women. Therefore, SERMs are more likely to be a competitor to existing and forthcoming bisphosphonates rather than HRT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Barrett-Connor E. Hormone replacement therapy. BMJ 1998; 317: 457–61

    Article  PubMed  CAS  Google Scholar 

  2. Torgerson DJ, Reid DM. The economics of osteoporosis and its prevention. Pharmaco Economics 1997; 11 (2): 126–38

    Article  CAS  Google Scholar 

  3. Torgerson DJ, Gosden T, Reid DM. The economics of osteoporosis prevention. Trends Endocrinol Metab 1997; 8: 236–9

    Article  PubMed  CAS  Google Scholar 

  4. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016–37

    PubMed  CAS  Google Scholar 

  5. Weinstein MC. Estrogen use in postmenopausal women - costs, risks, benefits. N Engl J Med 1980; 303: 308–16

    Article  PubMed  CAS  Google Scholar 

  6. Daly E, Gray A, Barlow D, et al. Measuring the impact of menopausal symptoms on quality of life. BMJ 1993; 307: 836–40

    Article  PubMed  CAS  Google Scholar 

  7. Eddy DM, Johnston CC, Cummings SR, et al. Osteoporosis: cost-effectiveness analysis and review of the evidence for prevention, diagnosis and treatment. Osteoporos Int 1998; 4 Suppl. 2: ii–vii

    Google Scholar 

  8. Dolan P, Torgerson DJ, Kumar TK. The effect of a Colle’s fracture on quality of life. Osteoporos Int 1999; 9: 196–9

    Article  PubMed  CAS  Google Scholar 

  9. Zethraeus N, Stromberg L, Jonsson B, et al. The cost of a hip fracture: estimates for 1709 patients in Sweden. Acta Orthop Scand 1997; 68: 13–7

    Article  PubMed  CAS  Google Scholar 

  10. Medical Research Council. Randomised comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in women with hysterectomy. BMJ 1996; 312: 473–8

    Article  Google Scholar 

  11. Torgerson DJ, Donaldson C, Russell IT, et al. Hormone replacement therapy: compliance and cost after screening for osteoporosis. Eur J Obstet Gynaecol Reprod Biol 1995; 59: 57–60

    Article  CAS  Google Scholar 

  12. Torgerson DJ, Thomas RE, Campbell MK, et al. Randomised trial of osteoporosis screening: HRT uptake and quality of life results. Arch Intern Med 1997; 157: 2121–5

    Article  PubMed  CAS  Google Scholar 

  13. Stevenson JC, Cust MP, Gangar KF, et al. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet 1990; 336: 265–9

    Article  PubMed  CAS  Google Scholar 

  14. Place VA, Powers M, Darley PE, et al. Adouble-blind comparative study of Estraderm and Premarin in the amelioration of postmenopausal symptoms. Am J Obstet Gynecol 1985; 152: 1092–9

    PubMed  CAS  Google Scholar 

  15. Lufkin EG, Wahner HW, O’Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992; 117: 1–9

    PubMed  CAS  Google Scholar 

  16. Komulainen MH, Kroger H, Tuppurainen MT, et al. HRT and Vit D in prevention of non vertebral fractures in postmenopausal women: a 5 year randomized trial. Maturitas 1998; 31: 45–54

    Article  PubMed  CAS  Google Scholar 

  17. Hulley S, Grady D, Bush T, et al. Randomised trial of estrogen and progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605–13

    Article  PubMed  CAS  Google Scholar 

  18. Royal College of Physicians. Clinical guidelines for the prevention and treatment of osteoporosis. London: RCP, 1998

    Google Scholar 

  19. Cauley JA, Seeley DG, Ensrud K, et al. Estrogen replacement therapy and fractures in older women. Ann Intern Med 1995; 122: 9–16

    PubMed  CAS  Google Scholar 

  20. Michaelsson K, Baron JA, Farahmand BY, et al. Hormone replacement therapy and the risk of hip fracture: population based case-control. BMJ 1998; 316: 1858–63

    Article  PubMed  CAS  Google Scholar 

  21. Collaborative group on hormonal factors in breast cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 without breast cancer. Lancet 1997; 350: 1047–59

    Article  Google Scholar 

  22. Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ 1997; 315: 149–53

    Article  PubMed  CAS  Google Scholar 

  23. Tosteson ANA, Weinstein M. Cost-effectiveness of hormone replacement therapy after the menopause. Baillieres Clin Obstet Gynaecol 1991; 5: 943–59

    Article  PubMed  CAS  Google Scholar 

  24. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312: 1254–59

    Article  PubMed  CAS  Google Scholar 

  25. Torgerson DJ, Reid DM. Estimating the cost effectiveness of screening tests. QJM 1997; 90 (10): 649–52

    Article  PubMed  CAS  Google Scholar 

  26. Cauley JA, Lucas FL, Kuller LH, et al. Bone mineral density and risk of breast cancer in older women. JAMA 1996; 276 (17): 1404–8

    Article  PubMed  CAS  Google Scholar 

  27. Zhang Y, Kiel DP, Kreger BE, et al. Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med 1997; 336: 611–7

    Article  PubMed  CAS  Google Scholar 

  28. Johansen A, Evans RJ, Stone MD, et al. Fracture incidence in England and Wales: a study based on the population of Cardiff. Injury 1997; 28: 655–60

    Article  PubMed  CAS  Google Scholar 

  29. Torgerson DJ, Campbell MK, Thomas RE, et al. Prediction of perimenopausal fractures by bone mineral density and other risk factors. J Bone Miner Res 1996; 11 (2): 293–7

    Article  PubMed  CAS  Google Scholar 

  30. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337: 1641–7

    Article  PubMed  CAS  Google Scholar 

  31. Ettinger B, Black D, Cummings S, et al. Raloxifene reduces the risk of incident vertebral fractures: 24-month interim analyses. Osteoporos Int 1998; 9 Suppl. 3: 11

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre for Health Economics and Department of Health Studies, University of York, York, YO10 5DD, England

    David J. Torgerson

  2. Department of Medicine and Therapeutics, University of Aberdeen, Foresterhill Medical School, Aberdeen, Scotland

    David M. Reid

Authors
  1. David J. Torgerson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David M. Reid
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David J. Torgerson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Torgerson, D.J., Reid, D.M. The Pharmacoeconomics of Hormone Replacement Therapy. Pharmacoeconomics 16, 9–16 (1999). https://doi.org/10.2165/00019053-199916010-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199916010-00002

Keywords

Search

Navigation